Mechanism of action of and resistance to quinolones

被引:63
作者
Bearden, DT
Danziger, LH
机构
[1] Univ Illinois, Coll Pharm, Dept Pharm Practice MC886, Sect Infect Dis Pharmacotherapy, Chicago, IL 60612 USA
[2] Oregon State Univ, Coll Pharm, Portland, OR USA
来源
PHARMACOTHERAPY | 2001年 / 21卷 / 10期
关键词
D O I
10.1592/phco.21.16.224S.33997
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A topoisomerase was identified as the bacterial target site for quinolone action in the late 1970s. Since that time, further study identified two bacterial topoisomerases, DNA gyrase and topoisomerase IV, as sites of antibacterial activity DNA gyrase appears to be the primary quinolone target for gramnegative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms, but this varies with the drug. Three mechanisms of resistance against quinolones are mutations of topoisomerases, decreased membrane permeability, and active drug efflux. Although these mechanisms occur singly, several resistance factors are often required to produce clinically applicable increases in minimum inhibitory concentrations. Appropriate drug selection and dosage and prudent human and veterinary interventions are important factors in controlling the emergence of resistance.
引用
收藏
页码:224S / 232S
页数:9
相关论文
共 88 条
[1]  
ACAR JF, 1997, CLIN INFECT DIS S1, V24, P67
[2]   Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus [J].
Aeschlimann, JR ;
Dresser, LD ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :335-340
[3]   BACTERIAL-RESISTANCE TO FLUOROQUINOLONES - LESSONS TO BE LEARNED [J].
BALL, P .
INFECTION, 1994, 22 :S140-S147
[4]  
Ball P, 1998, QUINOLONES, 2ND EDITION, P1
[5]   Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae [J].
Baranova, NN ;
Neyfakh, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1396-1398
[6]   Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance [J].
Bast, DJ ;
Low, DE ;
Duncan, CL ;
Kilburn, L ;
Mandell, LA ;
Davidson, RJ ;
de Azavedo, JCS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3049-3054
[7]   Structure of DNA topoisomerases [J].
Berger, JM .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :3-18
[8]   Fluoroquinolone-resistant Haemophilus influenzae:: Frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America) [J].
Biedenbach, DJ ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (04) :255-259
[9]   Isolation and characterization of a ciprofloxacin-resistant isolate of Haemophilus influenzae from The Netherlands [J].
Bootsma, HJ ;
Troelstra, A ;
vanVeenRutgers, A ;
Mooi, FR ;
deNeeling, AJ ;
Overbeek, BP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (02) :292-293
[10]   Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV [J].
Breines, DM ;
Ouabdesselam, S ;
Ng, EY ;
Tankovic, J ;
Shah, S ;
Soussy, CJ ;
Hooper, DC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :175-179